Statins as a new therapeutic approach in dedifferentiated thyroid cancer?

NuklearMedizin

Volumn 45, Issue 3, 2006, Pages

  Hofmann, A ^a   John, P ^a   Schaffarich, M P ^a   Sinzinger, H ^a   Staudenherz, A ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

RADIOACTIVE IODINE; RADIOISOTOPE; RECOMBINANT THYROTROPIN; SIMVASTATIN; SIMVATIN; THYROGLOBULIN;

ABSENCE OF SIDE EFFECTS; AGED; ANAMNESIS; ARTICLE; CASE REPORT; CERVICAL SPINE; CLINICAL FEATURE; ECHOGRAPHY; EXCRETION; FEMALE; HIP; HOSPITAL ADMISSION; HUMAN; LUNG; PELVIS; POSITRON EMISSION TOMOGRAPHY; SCINTIGRAPHY; THORAX RADIOGRAPHY; THYROID CANCER; THYROIDECTOMY;

HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IODINE RADIOISOTOPES; THYROID NEOPLASMS;

EID: 33745899319     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Agarwal B, Bhendwal S, Halmos B et al. Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells. Clin Cancer Res 1999; 5: 2223-9.
2. Ashcraft MW, van Herle AJ. The comparative value of serum thyroglobulin measurements and iodine 131 total body scans in the follow-up study of patients with treated differentiated thyroid cancer. Am J Med 1981; 71: 806-14.
3. Dimitroulakos J, Marhin WH, Tokunaga J et al. Microarray and biochemical analysis of lovastatin-induced apoptosis of squamous cell carcinomas. Neoplasia 2002; 4: 337-46.
4. Feleszko W, Mlynarczuk I, Olszewska D et al. Lovastatin potentiates antitumor activity of doxorubicin in murine melanoma via an apoptosis-dependent mechanism. Int J Cancer 2002; 100: 111-8.
5. Goretzki PE, Simon D, Frilling A et al. Surgical reintervention for differentiated thyroid carcinoma. Br J Surg 1993; 80: 1009-12.
6. Gray-Bablin J, Rao S, Keyomarsi K. Lovastatin induction of cyclin-dependent kinase inhibitors in human breast cells occurs in a cell cycle-independent fashion. Cancer Res 1997; 57: 604-9.
7. Gruning T, Tiepolt C, Zophel K et al. Retinoicacid for redifferentiation of thyroid cancer - does it hold its promise? Eur J Endocrinol 2003; 148: 395-402.
8. Grunwald F, Menzel C, Bender H et al. Redifferentiation therapy-induced radioiodine uptake in thyroid cancer. J Nucl Med 1998; 39: 1903-6.
9. Kim JS, Pirnia F, Choi YH et al. Lovastatin induces apoptosis in a primitive neuroectodermal tumor cell line in association with RB down-regulation and loss of the G1 checkpoint. Oncogene 2000; 19: 6082-90.
10. Kogan SC, Bishop JM. Acute promyelocytic leukemia: from treatment to genetics and back. Oncogene 1999; 18: 5261-7.
11. Maeda T, Matsunuma A, Kawane T et al. Simvastatin promotes osteoblast differentiation and mineralization in MC3T3-E1 cells. Biochem Biophys Res Commun 2001; 280: 874-7.
12. Mundy G, Garrett R, Harris S et al. Stimulation of bone formation in vitro and in rodents by statins. Science 1999; 286: 1946-9.
13. Pacini F, Lippi F, Formica N et al. Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels. J Nucl Med 1987; 28: 1888-91.
14. Park WH, Lee YY, Kim ES et al. Lovastatin-induced inhibition of HL-60 cell proliferation via cell cycle arrest and apoptosis. Anticancer Res 1999; 19: 3133-40.
15. Schmutzler C, Winzer R, Meissner-Weigl J et al. Retinoic acid increases sodium/iodide symporter mRNA levels in human thyroid cancer cell lines and suppresses expression of functional symporter in nontransformed FRTL-5 rat thyroid cells. Biochem Biophys Res Commun 1997; 240: 832-8.
16. Schmutzler C. Regulation of the sodium/iodine symporter by retinoids - a review. Exp Clin Endocrinol Diabetes 2001; 109: 41-4.
17. 131I therapy for elevated thyroglobulin levels. Thyroid 1997; 7: 273-6.
18. Simon D, Kohrle J, Schmutzler C et al. Redifferentiation therapy of differentiated thyroid carcinoma with retinoic acid: basics and first clinical results. Exp Clin Endocrinol Diabetes 1996; 104 (1 Suppl 4): 13-5.
19. Simon D, Koehrle J, Reiners C et al. Redifferentiation Therapy with retinoids: therapeutic option for advanced follicular and papillary thyroid cancer. World J Surg 1998; 22: 569-74.
20. Sinzinger H, Laimer H, Hoppichler F et al. Die 5 goldenen Regeln. Österr Arzteztg 2002; 12: 38-9.
21. Thibault A, Samid D, Tompkins AC et al. Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res 1996; 2: 483-91.
22. Van de Donk NW, Kamphuis MM, Lokhorst HM et al. The cholesterol lowering drug lovastatin induces cell death in myeloma plasma cells. Leukemia 2002; 16: 1362-71.
23. Van Herle AJ, Agatep ML, Padua DN et al. Effects of 13 cis-retinoic acid on growth and differentiation of human follicular carcinoma cells (UCLA RO 82 W-1) in vitro. J Clin Endocrinol Metab 1990; 71: 755-63.
24. Vitale M, Di Matola T, Rossi G et al. Prenyltransferase inhibitors induce apoptosis in proliferating thyroid cells through a p53-independent, CrmA-sensitive, and caspase-3-like protease-dependent mechanism. Endocrinology 1999; 140: 698-704.
25. Wang CY, Zhong WB TC, Lai SM et al. Lovastatin, a 3-hydroxy-3- methylglutaryl coenzym A reductase inhibitor, induces apoptosis and differentiation in human anaplastic thyroid carcinoma cells. J Clin Endocrinol Metab 2003; 88: 3021-6.
26. Weber C, Erl W, Weber PC. Lovastatin induces differentiation of Mono Mac 6 cells. Cell Biochem Funct 1995; 13: 273-7.